Using cutting-edge gene editing, synthetic biology and chromosome engineering technologies, we are generating several novel genetic platforms to enable the production of single domain antibodies (nanobodies), bispecific antibodies, and conventional tetrameric antibodies of human or other species for developing next generation diagnostic and therapeutic antibodies.
The first genetic platform includes a series of Singularity Mice® that robustly produce mouse or human heavy chain antibodies upon antigen challenge. A rapid NGS-driven pipeline has been established to profile, select, clone, and express nanobodies for large-scale high-throughput screens to identify target-specific binders for developing fully human nanobody-based next generation biologics, such as multi-specific antibodies, intracellular antibodies, deep-tissue/BBB penetrating nanobodies, and CAR-T/CAR-NK therapies.
From Musculus to Sapiens
The Road to Singularity
NGS-Driven Nanobody Binder Screen Pipeline
High Affinity and Neutralizing Potency of COVID Nanobodies
Singularity Mice Powered Biologics Drug Discovery
© 2017-2022 Leveragen, Inc. All rights reserved.